Regulus Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Regulus Therapeutics has a total shareholder equity of $86.8M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $93.8M and $7.0M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$87.31m |
| Equity | US$86.81m |
| Total liabilities | US$6.96m |
| Total assets | US$93.76m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 7RG0's short term assets ($91.7M) exceed its short term liabilities ($6.5M).
Long Term Liabilities: 7RG0's short term assets ($91.7M) exceed its long term liabilities ($476.0K).
Debt to Equity History and Analysis
Debt Level: 7RG0 is debt free.
Reducing Debt: 7RG0 currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 7RG0 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 7RG0 has sufficient cash runway for 2.1 years if free cash flow continues to grow at historical rates of 0.2% each year.